An investigation on behalf of investors of Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares over potential securities laws violations by Helius Medical Technologies and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Helius Medical Technologies, Inc. (NASDAQ: HSDT) concerning whether a series of statements by Helius Medical Technologies regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Newtown, PA based Helius Medical Technologies, Inc., a medical technology company, focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma.

On January 22, 2019, an article was published stating that Helius Medical Technologies phase III trial missed its primary effectiveness endpoint and that Helius has redacted important trial info. The article further states that the founders have a history of questionable marketing practices and that the former CEO is now a fugitive.